Iron chelation therapy with deferiprone improves oxidative status and red blood cell quality and reduces redox-active iron in β-thalassemia/hemoglobin E patients

• Main Authors: Noppawan Phumala Morales, Supot Rodrat, Pannaree Piromkraipak, Paveena Yamanont, Kittiphong Paiboonsukwong, Suthat Fucharoen
• Other Authors: Mahidol University
• Format: Article
• Published: 2022
• Subjects: Pharmacology, Toxicology and Pharmaceutics
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/75263

The oxidative status of twenty-three β-thalassemia/hemoglobin E patients was evaluated after administration of 75 mg/kg deferiprone (GPO-L-ONE®) divided into 3 doses daily for 12 months. Serum ferritin was significantly decreased; the median value at the initial and final assessments was 2842 and 17...